A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword
